Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 15 February 2017, 09:45 to 19:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens Present for all notes
2. Professor Kathryn Abel Present for notes 01 – 41
3. Mr Kamal Balakrishnan Present for all notes
4. Mr Michael Chambers Present for all notes
5. Gail Coster Present for all notes
6. Dr Prithwiraj Das Present for notes 18 – 52
7. Mr John P Hampson Present for all notes
8. Dr Nigel Langford Present for all notes
9. Professor Andrea Manca Present for all notes
10. Professor Eugene Milne Present for all notes
11. Professor Stephen O’Brien Present for all notes
12. Professor Andrew Renehan Present for all notes
13. Professor Peter Selby Present for all notes
14. Professor Matt Stevenson Present for notes 01 – 17 and 30 – 52
15. Dr Paul Tappenden Present for all notes
16. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheryl Hinds</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Abitha Senthinathan</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 01 - 17</td>
</tr>
<tr>
<td>Carl Prescott</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>Present for notes 01 - 17</td>
</tr>
<tr>
<td>Hamish Lunagaria</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 18 – 29</td>
</tr>
<tr>
<td>Ian Watson</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>Present for notes 18 – 29</td>
</tr>
<tr>
<td>Anna Brett</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 30 – 41</td>
</tr>
<tr>
<td>Nicola Hay</td>
<td>Technical Adviser, National Institute for Health and Care Excellence</td>
<td>Present for notes 30 – 52</td>
</tr>
<tr>
<td>Thomas Paling</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 42 – 52</td>
</tr>
<tr>
<td>Linda Landells</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>Present for notes 42 -52</td>
</tr>
</tbody>
</table>

**Non-public attendees:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Inigo Bermejo</td>
<td>ERG representative</td>
<td>Present for notes 06 - 14</td>
</tr>
<tr>
<td>Dr Edith Poku</td>
<td>ERG representative</td>
<td>Present for notes 06 - 14</td>
</tr>
<tr>
<td>Hazel Y Squires</td>
<td>ERG representative</td>
<td>Present for notes 06 – 14</td>
</tr>
<tr>
<td>Peter Cain</td>
<td>ERG representative</td>
<td>Present for notes 18 - 26</td>
</tr>
<tr>
<td>Steve Edwards</td>
<td>ERG representative</td>
<td>Present for notes 18 - 26</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and 42 – 49</td>
</tr>
</tbody>
</table>
The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of adalimumab and dexamethasone for treating non-infectious uveitis, carfilzomib for treated multiple myeloma, nivolumab for treating relapsed or refractory classical Hodgkin lymphoma and brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma.

The Chair welcomed Mr John Hampson to their first meeting as a member of the Appraisal Committee.

The Chair informed the Committee of the non-public observers at this meeting: Christopher Eatough, Leslie Hay, Helen Knight, Kirsty Pitt and Sarah Richards.

Apologies were received from David Chandler, Dr Iain Miller and Robert Walton.

Any other Business

None

Appraisal of adalimumab and dexamethasone for treating non-infectious uveitis

Part 1 – Open session
6. The Chair welcomed the invited experts: Alison Mapstone, Maxine McCarthy, Professor Philip Murray, Dr Srilakshmi Sharma and Nicola Symes as well as the Evidence Review Group - Dr Inigo Bermejo Dr Edith Poku and Hazel Y Squires to the meeting and they introduced themselves to the Committee.

7. The Chair welcomed company representatives from AbbVie and Allergan to the meeting.

8. The Chair asked all Committee members to declare any relevant interests

8.1. Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr Michael Chambers, Gail Coster, Mr John P Hampson, Dr Nigel Langford, Professor Andrea Manca, Professor Eugene Milne, Professor Stephen O'Brien, Professor Andrew Renehan, Dr Pete Selby, Professor Matt Stevenson and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

8.2. Dr Paul Tappenden declared a non-personal specific financial interest as he provided an internal peer review of the Assessment Group report, although he had not been directly involved.

8.2.1. It was agreed that this declaration would not prevent Dr Paul Tappenden from participating in this section of the meeting.

8.3. Dr Prithwiraj Das is conflicted as his organisation (Boehringer Ingelheim) has a biosimilar to adalimumab in the pipeline.

9. The Chair asked all NICE Staff to declare any relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

10. The Chair asked all other invited guests (assessment group and invited experts, not including observers) to declare their relevant interests.

10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab and dexamethasone for treating non-infectious uveitis.

11. The Chair introduced the lead team, Gail Coster, Professor Andrea Manca and Dr Judith Wardle who gave presentations on the clinical effectiveness and cost effectiveness of adalimumab and dexamethasone for treating non-infectious uveitis.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.

16. The Committee continued to discuss the clinical and cost effectiveness of adalimumab and dexamethasone for treating non-infectious uveitis.

16.1. The committee decision was based on consensus.

17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of carfilzomib for treated multiple myeloma [ID934]

Part 1 – Open session

18. The Chair welcomed the invited experts: Peter Clark, Peter Cain, Steve Edwards and Victoria Wakefield to the meeting and they introduced themselves to the Committee.

19. The Chair welcomed company representatives from Amgen to the meeting.

20. The Chair asked all Committee members to declare any relevant interests

20.1. Professor Andrew Stevens, Professor Kathryn Abel, Mr Kamal Balakrishnan, Mr Michael Chambers, Gail Coster, Dr Prithwiraj Das, Mr John P Hampson, Dr Nigel Langford, Professor Stephen O’Brien, Professor Andrew Renehan, Dr Pete Selby, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

20.2. Professor Andrea Manca declared a non-personal specific financial interest as co-investigator in two research grants relating to multiple myeloma (a NIHR PGfAR project and the recently funded EU IMI2 “HARMONY” project).

20.2.1. It was agreed that this declaration would not prevent Professor Andrea Manca from participating in this section of the meeting.
20.3. Professor Matt Stevenson is conflicted as he has received payment from by Onyx who previously held the rights to carfilzomib to comment on their STA submission. Onyx were then taken over by Amgen and he has done no further work.

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

22. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of carfilzomib for treated multiple myeloma.

23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Committee continued to discuss the clinical and cost effectiveness of carfilzomib for treated multiple myeloma.

28.1. The committee decision was based on consensus.

29. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
Appraisal of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma [ID972]

Part 1 – Open session

30. The Chair welcomed the invited experts: Dr Cathy Burton, Peter Clark, Graham Collins, Kate Comney, Ellie Philpotts, Keith Cooper, Jo Picot and Micah Rose to the meeting and they introduced themselves to the Committee.

31. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

32. The Chair asked all Committee members to declare any relevant interests.

32.1. Professor Kathryn Abel, Mr Kamal Balakrishnan, Gail Coster, Dr Prithviraj Das, Mr John P Hampson, Dr Nigel Langford, Professor Eugene Milne, Professor Andrew Renehan, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma.

32.2. Mr Michael Chambers declared a personal specific financial interest as he is involved currently funded by Takeda Pharmaceuticals (possible comparator company) as part of their contribution to the IMI GetReal project. The funding (now scheduled to end in Jun 2017) enables Mr Chambers to undertake general project activities, which have not been specific to any of Takeda's medicines.

32.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

32.3. Professor Andrea Manca declared a personal non-specific financial interest as he had received grants for funding in the disease area.

32.3.1. It was agreed that this declaration would not prevent Professor Andrea Manca from participating in this section of the meeting.

32.4. Professor Stephen O'Brien declared a non-personal non-specific financial interest as his organisation has received research funding from Bristol-Myers Squibb for clinical trials in CML.

32.4.1. It was agreed that this declaration would not prevent Professor Stephen O'Brien from participating in this section of the meeting.

33. The Chair asked all NICE Staff to declare any relevant interests.

33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma.
34. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

34.1. Dr Cathy Burton, Peter Clark, Keith Cooper, Kate Corney, Ellie Philpotts, Jo Picot and Micah Rose declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma.

34.2. Graham Collins declared a personal non-specific financial interest as he has received funding to attend training from Bristol-Myers Squibb Pharmaceuticals.

34.2.1. It was agreed that this declaration would not prevent Graham Collins from participating in this section of the meeting.

35. The Chair introduced the lead team, Dr Nigel Langford, Professor Stephen O’Brien, Dr Judith Wardle who gave presentations on the clinical effectiveness and cost effectiveness of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma.

36. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

37. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

38. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

39. Discussion on confidential information continued. This information was supplied by the company.

40. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for treating relapsed or refractory classical Hodgkin lymphoma.

40.1. The committee decision was based on consensus.

41. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of Brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma [ID722]

Part 1 – Open session
42. The Chair welcomed the invited experts: Peter Clark, Kate Corney, Karl Peggs, Kim Linton, John Radford, Peter Cain, Steve Edwards and Tracey Jhita to the meeting and they introduced themselves to the Committee.

43. The Chair welcomed company representatives from Takeda UK Ltd to the meeting.

44. The Chair asked all Committee members to declare any relevant interests

44.1. Mr Kamal Balakrishnan, Gail Coster, Dr Prithviraj Das, Mr John P Hampson, Dr Nigel Langford, Professor Eugene Milne, Professor Stephen O’Brien, Professor Andrew Renehan, Dr Peter Selby, Professor Matt Stevenson, Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

44.2. Mr Michael Chambers declared a personal specific financial interest as he is involved currently funded by Takeda Pharmaceuticals (possible comparator company) as part of their contribution to the IMI GetReal project. The funding (now scheduled to end in Jun 2017) enables Mr Chambers to undertake general project activities, which have not been specific to any of Takeda’s medicines.

44.2.1. It was agreed that this declaration would not prevent Mr Michael Chambers from participating in this section of the meeting.

44.3. Professor Andrea Manca declared a personal non-specific financial interest as he had received grants for funding in the disease area.

44.3.1. It was agreed that this declaration would not prevent Professor Andrea Manca from participating in this section of the meeting.

45. The Chair asked all NICE Staff to declare any relevant interests.

45.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

46. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

46.1. Peter Clark, Kate Corney, Kim Linton, Peter Cain, Steve Edwards and Tracey Jhita declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.
46.2. Karl Peggs declared a personal non-specific financial interest as he had received funding from the company Takeda for travel expenses in the past.

46.2.1. It was agreed that this declaration would not prevent Karl Peggs from participating in this section of the meeting.

46.3. John Radford declared a personal non-specific financial interest as a chief clinical trial investigator.

46.3.1. It was agreed that this declaration would not prevent John Radford from participating in this section of the meeting.

The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

47. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

48. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

49. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

50. Discussion on confidential information continued. This information was supplied by the company.

51. The Committee continued to discuss the clinical and cost effectiveness of brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma.

51.1. The committee decision was based on consensus.

52. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

53. Thursday 16 March 2017 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.